Core Viewpoint - Dongxing Medical announced plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd. through cash payment, which, if successfully executed, will make Wuhan Yijiaobao a subsidiary of the company [1] Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies" [1] - The acquisition does not involve the issuance of shares by the listed company, nor does it constitute a related party transaction [1] - The transaction will not lead to changes in the controlling shareholder or actual controller of the listed company [1]

证券代码：301290 证券简称：东星医疗 公告编号：2025-057 江苏东星智慧医疗科技股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年10月24日，公司披露了《关于筹划重大资产重组的进展公告》（公告编 号：2025-043）。 2025年11月26日，公司披露了《关于筹划重大资产重组的进展公告》（公告编 号：2025-048）。 截至本公告披露之日，标的公司的审计、评估工作仍在进行中，预计尚需一定 时间完成，公司及相关各方正在积极推进本次交易的相关工作，后续公司亦将按照 相关法律法规的规定及时披露项目进展情况。 三、风险提示 一、交易概述 江苏东星智慧医疗科技股份有限公司（以下简称"公司"或"上市公司"） 拟以支付现金方式购买武汉医佳宝生物材料有限公司（以下简称"武汉医佳宝" 或"标的公司"）90%的股权（以下简称"本次交易"），本次交易如能顺利实 施，武汉医佳宝将成为公司的控股子公司。 根据初步研究和测算，本次交易预计构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易不涉及上市公司 ...

Group 1 - The core point of the article is that Dongxing Medical has reported a total of 9,304 shareholders as of December 19, 2025, including credit accounts [2]

Core Viewpoint - The company, Arctech, announced that its shareholder, Wuxi Yuanhe Zhongyuan YouNeng Venture Capital Partnership (Limited Partnership), has reduced its stake in the company by 54,601,378 shares, representing 1.50% of the total share capital [1] Summary by Categories Shareholder Activity - Wuxi Yuanhe Zhongyuan has reduced its holdings through both centralized bidding and block trading, with 36,782,173 shares sold via centralized bidding and 17,819,205 shares sold through block trading [1] - The reduction plan has reached its time limit, with the share price during the reduction ranging from 9.60 to 23.49 yuan per share, resulting in a total reduction amount of 778 million yuan [1] - Following the reduction, Yuanhe Zhongyuan's shareholding percentage decreased from 2.07% to 0.57% [1]

Group 1 - The core point of the article is that Dongxing Medical announced the approval of several proposals at its third extraordinary general meeting of shareholders in 2025, including the use of part of its idle raised funds and self-owned funds for cash management [2] Group 2 - The announcement indicates a strategic move by the company to optimize its financial resources [2] - The decision reflects the company's ongoing efforts to enhance its capital management practices [2]

证券代码：301290 证券简称：东星医疗 公告编号：2025-056 江苏东星智慧医疗科技股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 6、本次股东会的召集、召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程的规定。 （二）会议出席情况 1、出席会议的总体情况 本次会议现场出席及网络出席的股东和股东代表共 81 人，代表股份 1、会议召开的时间： （1）现场会议时间：2025年12月19日（星期五）下午2:30； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年12 月19日上午9:15-9:25，9:30—11:30，下午13:00—15:00；通过深圳证券交易所互 联网投票系统投票的时间为2025年12月19日上午9:15至下午3:00的任意时间。 2、会议召开方式：本次股东会采用现场投票与网络投票相结合的方式。 3、会议召开地点： ...

北京市天元律师事务所 关于江苏东星智慧医疗科技股份有限公司 2025 年第三次临时股东会的法律意见 京天股字（2025）第 758 号 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》和《律 师事务所证券法律业务执业规则（试行）》等规定及本法律意见出具日以前已经发生 或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充 分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发表的结论性意 见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 1 本所及经办律师同意将本法律意见作为本次股东会公告的法定文件，随同其他公 告文件一并提交深圳证券交易所予以审核公告，并依法对出具的法律意见承担责任。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对公司提供 的文件和有关事实进行了核查和验证，现出具法律意见如下： 一、 本次股东会的召集、召开程序 公司第四届董事会于 2025 年 12 月 3 日召开第十四次会议作出决议召集本次股 东会，并于 2025 年 12 月 4 日通过指定信息披露媒体发出了《召开股东会通知》。 《召开股东会通知》中 ...

Core Insights - The open stapler market in China is experiencing a declining trend, with the market size expected to reach 1.41 billion yuan in 2024, a year-on-year decrease of 2.1% [1][10] - The decline is primarily attributed to the shift towards minimally invasive surgical techniques, with laparoscopic staplers becoming the mainstream choice due to their advantages in reducing trauma and improving recovery times [1][10] - Despite the decline, open staplers still hold irreplaceable value in grassroots medical settings and complex surgeries, indicating potential stabilization in market size [1][10] Industry Overview - Open staplers are primarily used in traditional open surgeries, offering advantages such as quick suturing, ease of use, and reduced risk of cross-infection [3] - The types of open staplers include linear staplers, circular digestive tract staplers, and others, with a growing trend towards laparoscopic staplers due to their enhanced safety and efficiency [4][5] Market Dynamics - The open stapler market in China saw a decline from 1.53 billion yuan in 2020 due to the pandemic, with a recovery in 2021 followed by a projected decline from 2022 to 2024 [10][11] - The global open stapler market is expected to reach 3.34 billion USD by 2024, reflecting a slow growth rate influenced by the expansion of laparoscopic staplers [10] Competitive Landscape - The market remains competitive, with foreign giants like Johnson & Johnson and Medtronic dominating the high-end segment due to their technological advantages [12] - Domestic companies are leveraging local production to control costs and meet the needs of hospitals, with some products nearing the performance of foreign brands [12] Key Players - Notable companies in the open stapler industry include Dongxing Medical, Lepu Medical, and David Medical, which are focusing on product innovation and cost-effective solutions [2][12][13] Development Trends - Continuous optimization of technology in open staplers is expected, focusing on safety, efficiency, and precision [14] - The integration of automation and standardization features is anticipated, aiming to reduce reliance on surgeon experience and enhance surgical quality [15] - Future demand will likely concentrate on specific fields, particularly in grassroots healthcare and complex surgical scenarios, emphasizing differentiated competition [16]

Group 1 - The core point of the article is that Dongxing Medical (301290) reported a total of 9,582 shareholders as of December 10, 2025, including credit accounts [1]

Group 1 - Dongxing Medical (301290.SZ) announced a share reduction plan by shareholder Jiang Shihua, who holds 5,070,000 shares (5.0612% of total shares) [1] - Jiang plans to reduce up to 986,806 shares (not exceeding 0.9851% of total shares) within two months from December 29, 2025, through centralized bidding or block trading [1] - The reduction will not change the company's control or affect its ongoing operations, as Jiang is not a controlling shareholder [1] Group 2 - Dongxing Medical raised a total of 1,104.16 million yuan in its IPO, with a net amount of 1,002.57 million yuan after deducting issuance costs [2] - The final net fundraising amount exceeded the original plan by 389.62 million yuan [2] - The funds are intended for projects including intelligent manufacturing of medical device components and the development of new minimally invasive surgical products [2]